In Vitro Fertilization: Expensive, 2.6% of US births, 18% of Japanese births (consider Vitamin D)
IVF is quietly reshaping birth rates in rich countries
By Claude, AI April 2026, PDF has the hyperlinks
One in 38 American babies born in 2022 was conceived through IVF, and by 2024 that share had climbed past one in 36 — but the US still trails the developed world by a wide margin. In Japan, nearly 1 in 8 babies born in 2023 came from assisted reproductive technology (ART); in Denmark, the share approaches 1 in 12; in Belgium, Czech Republic, Australia and Israel, it sits above 1 in 20. The gap reflects policy, not biology. Countries where the state pays for IVF — typically 3 to 6 cycles at full or near-full cost — deliver two to five times the utilization of countries where patients pay out of pocket. As fertility rates collapse across the developed world, IVF is moving from a private medical service into a core pillar of demographic policy, and the US is an outlier for how much it leaves to the patient's checkbook.
The story below synthesizes CDC ART Surveillance data, SART national summaries, ESHRE's European IVF Monitoring (EIM) reports in Human Reproduction, ICMART world reports, ANZARD (Australia/NZ), HFEA (UK), JSOG (Japan), CARTR Plus (Canada), and the Fertility Europe 2024 policy atlas. Where registry definitions diverge — notably on whether intrauterine insemination (IUI) counts as "ART" — we flag it explicitly.
The US trajectory: a tripling in two decades, with acceleration after 2020
The share of US babies born via ART has roughly tripled since 2000, with growth accelerating sharply after 2020 even as total US births declined. In 2000, the CDC recorded about 35,000 ART infants out of 4.06 million births (0.86%). By 2010 the share had reached roughly 1.5%, by 2018 about 2.2%, and in 2022 it hit the widely cited 2.6% — 98,289 infants from 435,426 ART cycles at 457 clinics. SART's 2024 release reported 100,158 IVF babies, the first time US ART births crossed 100,000 in a single year, equivalent to roughly 2.76% or 1 in 36 babies when set against provisional NCHS total births of about 3.62 million.
| Year | ART cycles | IVF/ART infants born | Total US births | % of US births via ART |
|---|---|---|---|---|
| 2000 | 99,629 | 35,025 | 4,058,814 | ~0.86% |
| 2005 | 134,260 | 52,041 | 4,138,349 | ~1.26% |
| 2010 | 154,427 | 61,564 | 3,999,386 | ~1.54% |
| 2015 | 231,936 | 71,152 | 3,978,497 | ~1.79% |
| 2018 | 306,197 | 81,478 | 3,791,712 | ~2.15% |
| 2020 | 326,468 | 79,942 | 3,613,647 | ~2.21% |
| 2022 | 435,426 | 98,289 | 3,667,758 | 2.6% |
| 2023 | 432,641 (SART) | 95,860 | 3,596,017 | ~2.67% |
| 2024 | 449,772 (SART) | 100,158 | 3,622,673 (prov.) | ~2.76% |
Underneath the headline, the clinical picture has transformed. Frozen embryo transfers now account for about 87% of cycles (up from roughly 20% in 2010), single-embryo transfer has risen from 15% in 2009 to about 79% in 2024, and the ART multiple-birth rate has collapsed from 53% in 2000 to roughly 2.6% today. Egg-banking cycles alone rose from 475 in 2009 to more than 184,000 in 2022 — a 388-fold increase that explains much of the apparent explosion in "cycles" without a proportionate rise in births. State variation is extreme: Washington DC (7.3%), Massachusetts (6.2%), and New Jersey (5.6%) already exceed the national average of high-income European countries, while Alabama, Arkansas, and Alaska sit below 1%. The concentration maps cleanly onto states with insurance mandates.
How the world ranks: Japan, Denmark and Belgium lap the US
The ranking below uses each country's most recent complete national registry data. ESHRE/ICMART define ART as IVF + ICSI + frozen embryo transfer + egg donation + PGT; IUI is excluded. Popular "Denmark 10%" claims typically bundle IUI in; the pure ART figure is lower.
| Rank | Country | % of births via ART | Year | Primary source |
|---|---|---|---|---|
| 1 | Japan | ~11.7% | 2023 | JSOG Registry (85,048 ART babies / ~727,000 births) |
| 2 | Denmark | ~8.5% (ART-only); ~10% incl. IUI | 2020–22 | ESHRE EIM; Taub Center |
| 3 | Iceland | ~6.3–8.5% | 2020 | ESHRE EIM 24th Report (Smeenk 2025) |
| 4 | Czech Republic | ~6.0–6.5% | 2020 | ESHRE EIM |
| 5 | Belgium | ~5.8% | 2019 | ESHRE EIM 23rd Report |
| 6 | Australia | 5.4% (women giving birth) | 2021 | ANZARD 2022 |
| 7 | Israel | ~5.0% | 2019 | Israel MoH via Taub Center |
| 8 | Slovenia | ~5.0–5.5% | 2019 | ESHRE EIM |
| 9 | Estonia | ~5.0% | 2019 | ESHRE EIM |
| 10 | Greece | ~5.0% | 2020 | ESHRE EIM |
| 11 | New Zealand | ~4.4% | 2022 | ANZARD 2022 |
| 12 | Finland | ~4.0% | 2020 | ESHRE EIM / Nordic Statistics |
| 13 | Sweden | ~3.5–4.0% | 2020 | ESHRE EIM |
| 14 | France | ~3.6% | 2019 | Agence de la biomédecine |
| 15 | Norway | ~3.5% | 2020 | ESHRE EIM |
| 16 | Italy | ~3.5% | 2019 | Registro Nazionale PMA |
| 17 | Netherlands | ~3.5% | 2019 | Dutch NVOG |
| 18 | Spain | ~4–5% registered (up to 10% claimed, inflated by cross-border) | 2019 | Registro SEF |
| 19 | UK | 3.1% | 2023 | HFEA (20,700 births) |
| 20 | Germany | ~3.0% | 2020 | D·I·R Register |
| — | USA | 2.6% | 2022 | CDC ART Surveillance |
| 21 | Canada | 2.2% | 2022 | CARTR Plus (7,609 babies) |
South Korea likely exceeds 5% but has no official published percentage; government ART support data suggest utilization in the range of 8–10% after 2024 expansions, though this remains an estimate.
Japan's number is by far the most striking: ART accounted for roughly 2.7% of Japanese births in 2010 and 11.7% in 2023, reflecting both a surge in cycles after the April 2022 national insurance reform and a collapsing birth denominator (Japan's total births fell 40% in 15 years to roughly 727,000). A similar mechanical amplification is at work in Denmark, Italy, and South Korea, where low fertility inflates ART's share even without cycle growth.
Three distortions bear watching. Cross-border care heavily inflates Spain, Czech Republic, Greece, and Denmark — ESHRE 2020 counted roughly 42,000 cross-border cycles — so national registry figures capture cycles performed rather than babies born domestically. Loss-to-follow-up likely understates Italy, Spain, and France. And Israel's 5% looks low relative to its status as the world's highest-per-capita IVF user (over 5,700 cycles per million inhabitants) because roughly a third of Israeli cycles occur in women over 40, dragging down babies-per-cycle.
IVF is used most in those countries that pay for it
Public coverage is the single strongest predictor of utilization. Countries meeting ESHRE's 3,000-cycles-per-million demand threshold — Israel, Japan, Denmark, Czech Republic, Australia, Spain — all have either near-universal public funding or structured rebate programs. The US, at roughly 922 cycles per million, sits at about one-third of estimated demand.
| Country | Public coverage | Funded cycles | Age limit (woman) | Key eligibility rules | OOP per cycle |
|---|---|---|---|---|---|
| Israel | ~100% | Unlimited up to 2 live children, cap 8 per course since 2014 | 18–45 (51 w/ donor eggs) | No marital/orientation/income restriction | ~$100–170 fee |
| Denmark | ~100% public | 6 cycles for 1st child + 3 for 2nd (doubled 2024) | Referral <40; treatment to 41 | Single women/lesbians since 2006 | Free public |
| Belgium | ~90% | 6 IVF/ICSI + 6 IUI | <43 (transfer to 47) | Same-sex couples included; tied to eSET rules | ~€170 copay |
| France | 100% | 4 IVF + 6 IUI per child; resets on each child | <43 | Single women/lesbians since 2021 bioethics law | €0 |
| Sweden | ~100% public | 3 IVF or 6 IVF+IUI | <40 | Single women since 2016 | Free public |
| Norway | ~100% | ~3 cycles | ~39 practical | Single women since 2020 | Modest copay |
| Finland | ~100% | 3 IVF or 6 combined | No legal limit | Among most flexible Nordic systems | Low copay |
| Iceland | Public | 4 cycles | No age limit (unique in ESHRE survey) | Single women permitted | Low copay |
| Netherlands | Basic insurance | 3 fresh IVF | <43 | BMI limits common | ~€385 deductible |
| UK | NHS (postcode lottery) | NICE: 3 if <40, 1 if 40–42; reality 0–3 by ICB | 35–42 varies | Scotland 54% NHS-funded, England only 24%; 73% of UK cycles are self-funded | £5,000–10,000 private |
| Spain | SNS (regional) | 3 IVF + 4–6 IUI | <40 public | No prior children in public system | €0 public; €4,000–7,000 private |
| Czech Republic | Public insurance | 3 (or 4 w/ eSET) | <40 public; legal max ~48 | Heterosexual couples only | €1,500–3,000 private |
| Slovenia | National insurance | 6 cycles | <43 | Heterosexual couples only | Minimal |
| Germany | Statutory (GKV) | 50% of 3 cycles | 25–39 women; ≤49 men | Married heterosexuals federally; some Länder top up | €1,500–1,700 after 50% |
| Italy | SSN (regional) | Up to 6 (varies) | ~43 | Heterosexuals; donor gametes legal since 2014 | €3,000–5,500 private |
| Australia | Medicare rebate | No cycle limit (percentage rebate) | No federal cap | Medical infertility required; NSW added $2,000 rebate Feb 2025 | AUD $5,000–8,000 after rebate |
| New Zealand | Public in eligible regions | 2 treatment packages | <40 referral | BMI limits; no existing biological child | NZ $16,000–20,000 private |
| Japan | National insurance since April 2022 (70%) | 6 if <40; 3 if 40–42; none after 43 | 43 hard cap | Married/de facto; local govt top-ups | ~¥150,000 (~$1,000) |
| South Korea | NHI + local subsidies | Expanded 2024 to 25 per childbirth (Seoul); age 45+ cap lifted | 45+ allowed post-2024 | Unmarried eligible in Seoul | ₩300–500k copay |
| Canada | Province-by-province | Quebec: 1 IVF + unlimited IUI; Ontario: 1 IVF; NB/NL: $20k lifetime (2025); AB/BC: nothing | Varies | Residency | CAD $10,000–15,000 |
| USA | No federal mandate; Medicaid generally excludes IVF | 25 states + DC have some mandate; FEHB covers ≥3 cycles of IVF drugs | Varies by plan | ERISA self-insured plans exempt from state mandates | $15,000–30,000 |
The three most generous systems define the ceiling
Israel is in a category of its own. Under the 1995 National Health Insurance Law, women aged 18–45 receive unlimited IVF up to two live children with their current partner, regardless of marital status, sexual orientation, income, or prior children from other relationships. IVF consumes roughly 2% of Israel's entire national health budget. Attempts to ration have repeatedly collapsed under political pressure from a rare cross-ideological coalition of pronatalist religious conservatives, demographic-security hawks, feminists, and patient advocates. Israeli women undergo roughly twice the per-capita cycles of Danish women and five times the European average.
Denmark moved even further in 2024. Prime Minister Mette Frederiksen's New Year address announced a doubling of public coverage from 3 to 6 cycles for a first child, plus 3 additional cycles for a second child (effective December 2024, backed by 150 million DKK). The framing was explicitly demographic: with fertility below replacement, IVF is now treated as a pronatal policy instrument rather than a medical benefit. The share of Danish births from ART has been climbing toward the 10% range (including IUI).
Japan's 2022 reform is the natural experiment to watch. Before April 2022, IVF in Japan was subsidized but not insurance-covered. After the reform, ART patients increased about 4% overall — but patients aged 25–34 jumped 22.9%, and ART's share of all Japanese births reached roughly 10% in 2022 and 11.7% in 2023. This is the clearest modern evidence that public coverage doesn't just enable access; it shifts reproductive behavior toward earlier and more aggressive use of ART.
The US: a patchwork that leaves most Americans exposed
Twenty-five states plus DC have some form of fertility mandate, but only about 13 require meaningful IVF coverage, and even those mandates apply solely to fully insured plans regulated by the state. The states with the strongest IVF mandates — Massachusetts, New Jersey, Illinois, New York (3 cycles), Connecticut (2 cycles), Rhode Island, Delaware (6 retrievals plus unlimited transfers), Colorado, Maine, New Hampshire, Washington, Maryland, and California (SB 729, delayed to January 1, 2026) — collectively drive the utilization hotspots visible in CDC state data. DC's 7.3% and Massachusetts' 6.2% of births via ART exceed Belgium and approach Denmark, demonstrating that demand exists when cost is removed.
Three structural gaps blunt US utilization. First, roughly 65% of employer-insured workers are on self-insured ERISA plans exempt from state mandates; a mandate in Illinois or New York does not reach a Chicago or Manhattan employee whose employer self-funds.
Second, Medicaid essentially does not cover IVF in any state, though New York covers limited infertility drugs — a gap Nevada's governor cited in vetoing a 2025 expansion. Third, out-of-pocket costs remain stark: a full cycle runs $15,000–$30,000, and cumulative treatment often exceeds $60,000.
Note by Vitamin D Life: Employers could just pay $20 for the Vitamin D (female and male) in many cases and save $40,000
Recent federal movement has been substantial in rhetoric and modest in substance. The Federal Employee Health Benefits (FEHB) program expanded coverage in 2024 (IVF drugs for 3 cycles in all plans) and 2025 (every enrollee has at least two plan choices with IVF coverage, and two nationwide PPOs offer $25,000/year IVF benefits). TRICARE extended IVF benefits to unmarried service members and same-sex couples in March 2024 (up to 6 retrievals and 3 cycles, though service-connected infertility is still required for full coverage). President Trump's February 2025 executive order directed his Domestic Policy Council to recommend IVF cost-reduction measures within 90 days but imposed no coverage mandate; the more concrete follow-up was an October 2025 deal with EMD Serono providing an 84% discount on Gonal-f, Ovidrel, and Cetrotide through TrumpRx.gov starting January 2026. The Right to IVF Act and the Family Building FEHB Fairness Act (reintroduced February 2025) remain stalled in Congress, where 126 House Republicans have simultaneously signed the Life at Conception Act, which could threaten IVF via fetal personhood. The 2024 Alabama Supreme Court LePage ruling treating frozen embryos as "children" forced temporary clinic closures before a state liability shield restored operations, and it has become the central cautionary tale in the national debate.
What the comparison actually shows
The correlation between funding and utilization is real but not linear. Pearson coefficients of roughly 0.43 between GDP per capita and IVF utilization across European countries (Shalev-Shai et al.) and the clean before/after data from Japan's 2022 reform both support the thesis that public funding is the dominant policy lever. But Klitzman et al. (Human Reproduction 2013) found that once social eligibility rules — single-women access, same-sex couple access, age thresholds — are controlled for, funding level alone loses statistical significance. Germany illustrates the point: statutory insurance covers half of three cycles, relatively generous on paper, but the restriction to married heterosexual couples aged 25–39 holds utilization to about 3%, half of Belgium's rate with similar per-capita wealth.
The utilization-maximizing policy package — visible in Israel, Denmark, Belgium, France and increasingly Japan — combines four to six fully funded cycles, eligibility through at least age 42, no marital or sexual-orientation restrictions, coverage of a second child, and subsidized medications. Countries that hit all five levers cluster at 5% or above of all births via ART. Countries that offer partial funding with restrictive social rules cluster at 3%. Countries that leave IVF largely to patients and employers — the US, Canada, most of the UK — cluster at 2–3% despite sophisticated clinical sectors. The gap between the US and peer countries is not a demand gap or a clinical-capacity gap; it is a financing gap.
Conclusion: a policy lever with demographic consequences
IVF is transitioning from a discretionary medical service into an instrument of demographic policy, and the countries that recognize this first are reshaping their birth statistics fastest. Japan went from 2.7% of births via ART in 2010 to 11.7% in 2023 — the largest single-generation shift in developed-world reproductive behavior. Denmark's 2024 cycle-doubling, South Korea's 2024 eligibility expansion, and France's 2021 bioethics law all reflect governments treating IVF as a pronatal intervention at a time when total fertility rates have collapsed below replacement across nearly the entire OECD.
The US 2.6% figure should be read in that comparative frame. The country has the world's third-largest absolute IVF market and world-class clinical outcomes, but its utilization rate is roughly one-third of Japan's, one-third of Denmark's, and half of Belgium's. The gating factor is financial — specifically the ERISA exemption that leaves most employer-insured Americans outside state mandates, the absence of Medicaid IVF coverage, and the lack of a federal coverage floor. The 2024–2025 federal moves (FEHB expansion, TRICARE reform, drug-pricing deal, state mandates in California and DC) nudge the US toward the OECD norm but fall well short of the Israeli-Danish-Belgian model. If the US ever adopts a federal IVF coverage mandate, the precedents from Japan and Denmark suggest the share of American babies born via IVF could plausibly double within a decade — not because demand would grow from nothing, but because latent demand, currently priced out, would be unlocked.
Couples with >40ng of Vitamin D are 15% less likely to need IVF, and If take IVF, are 4X more likely to be successful
Related in VitaminDwiki
- In vitro fertilization and Vitamin D – many studies
- Birth rates doubled with Vitamin D - 300,000 IU for infertile men – RCT
Perhaps 2X less need for IVF if the male has enough Vitamin D - IVF 4X more successful for white women with lots of vitamin D – many studies
- Pregnancies are helped 10 ways by Vitamin D - umbrella analysis
- Low Vitamin D while pregnant - chart of possible problems
- Health Problems Associated with Low Vitamin D at Birth